GrantsAtlas
RollingStartups

Parkinson's Disease Therapeutics Pipeline Program

Funded by The Michael J. Fox Foundation for Parkinson's Research

The Michael J. Fox Foundation's flagship program funding preclinical and clinical development of new Parkinson's disease therapies, mainly for companies.

The Therapeutics Pipeline Program is the Michael J. Fox Foundation's flagship funding initiative for new Parkinson's disease treatments. It funds the development of therapies that could slow the disease or ease its symptoms, focusing on work that produces meaningful evidence at key development milestones. The program also supports tools that help teams make development decisions, such as biomarkers tied to a specific therapy.

The program is built around industry. Companies can apply on their own or in partnership with academic groups, which the foundation sees as a clearer path to commercialization, and some academic-led projects can qualify in certain cases. Applications start with a short pre-proposal that the foundation accepts on a rolling basis, and full proposals are by invitation only, reviewed in several cycles each year.

What it funds

  • Preclinical development of therapies for Parkinson's disease
  • Clinical development of disease-modifying or symptom-relieving treatments
  • Integration and analysis of biomarker tools that inform development decisions for a specific therapy
  • Not funded: early-stage target discovery, standalone biomarker discovery or platform work without a specific Parkinson's therapy, and simple reformulations of approved drugs without a strong rationale

Who can apply

  • Companies developing Parkinson's therapies
  • Partnerships between academic groups and industry
  • In certain cases, academic-led projects; the downloadable program overview explains when

How to apply

  1. Download the program overview and the preclinical or clinical application template from the program page
  2. Create an account in the foundation's grant application system
  3. Submit a pre-proposal; these are accepted on a rolling basis
  4. If invited, submit a full proposal; office hours are available after an invitation

Parkinson's Disease Therapeutics Pipeline Program: common questions

Can a company apply on its own?

Yes. The program is open to industry, as well as to academic and industry partnerships.

Can a university lab apply?

Academic-led projects can qualify in certain cases. The program overview on the official page explains the exemptions.

Is there a fixed deadline?

Pre-proposals are accepted on a rolling basis. Full proposals are by invitation and reviewed in several cycles each year.

What will the foundation not fund through this program?

Early-stage target discovery, standalone biomarker or platform work without a specific Parkinson's therapy, and simple reformulations of approved drugs without strong rationale.

Before you apply

Amounts, eligibility and deadlines change every cycle. Read the current solicitation on the official page before you start an application.

  1. 01Breakthrough Energy Explorer GrantBreakthrough EnergyGrants for early-stage, high-risk climate technology research, typically led by scientists in a university lab or research organization.RollingStartups
  2. 02Small Business Innovation Research (SBIR)US federal agencies (coordinated by SBA)Federal R&D funding for US small businesses developing technology with commercial potential. Eleven agencies run their own SBIR solicitations.StartupsSmall businesses
  3. 03Small Business Technology Transfer (STTR)US federal agencies (coordinated by SBA)Like SBIR, but the small business must partner with a US research institution such as a university or federal lab.StartupsSmall businesses